Alto Neuroscience (ANRO) Competitors $3.15 +0.03 (+0.96%) Closing price 08/15/2025 03:58 PM EasternExtended Trading$3.14 0.00 (-0.16%) As of 08/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANRO vs. ARCT, CRVS, ABEO, OLMA, ALDX, AMRN, BNTC, RCKT, INBX, and NGNEShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Arcturus Therapeutics (ARCT), Corvus Pharmaceuticals (CRVS), Abeona Therapeutics (ABEO), Olema Pharmaceuticals (OLMA), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Benitec Biopharma (BNTC), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Its Competitors Arcturus Therapeutics Corvus Pharmaceuticals Abeona Therapeutics Olema Pharmaceuticals Aldeyra Therapeutics Amarin Benitec Biopharma Rocket Pharmaceuticals Inhibrx Biosciences Neurogene Alto Neuroscience (NYSE:ANRO) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership. Do analysts recommend ANRO or ARCT? Alto Neuroscience currently has a consensus price target of $8.50, indicating a potential upside of 169.84%. Arcturus Therapeutics has a consensus price target of $50.00, indicating a potential upside of 156.67%. Given Alto Neuroscience's higher probable upside, equities analysts clearly believe Alto Neuroscience is more favorable than Arcturus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ANRO or ARCT? Alto Neuroscience has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Is ANRO or ARCT more profitable? Alto Neuroscience has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -49.26%. Arcturus Therapeutics' return on equity of -24.87% beat Alto Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets Alto NeuroscienceN/A -44.34% -36.73% Arcturus Therapeutics -49.26%-24.87%-17.75% Does the media refer more to ANRO or ARCT? In the previous week, Arcturus Therapeutics had 2 more articles in the media than Alto Neuroscience. MarketBeat recorded 31 mentions for Arcturus Therapeutics and 29 mentions for Alto Neuroscience. Arcturus Therapeutics' average media sentiment score of 0.45 beat Alto Neuroscience's score of 0.05 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 1 Very Positive mention(s) 4 Positive mention(s) 22 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arcturus Therapeutics 1 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, ANRO or ARCT? Alto Neuroscience has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlto NeuroscienceN/AN/A-$61.43M-$2.34-1.35Arcturus Therapeutics$152.31M3.47-$80.94M-$2.23-8.74 Do institutionals and insiders have more ownership in ANRO or ARCT? 94.5% of Arcturus Therapeutics shares are held by institutional investors. 11.1% of Alto Neuroscience shares are held by insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryArcturus Therapeutics beats Alto Neuroscience on 11 of the 15 factors compared between the two stocks. Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeuroscienceMED IndustryMedical SectorNYSE ExchangeMarket Cap$84.48M$3.10B$5.67B$20.96BDividend YieldN/A2.23%3.79%3.58%P/E Ratio-1.3220.3830.5827.94Price / SalesN/A368.96464.2456.18Price / CashN/A42.3037.4023.77Price / Book0.698.659.095.26Net Income-$61.43M-$54.65M$3.25B$994.11M7 Day Performance2.87%6.58%7.42%1.79%1 Month Performance17.54%7.54%5.50%1.73%1 Year Performance-66.35%13.73%30.67%13.35% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience1.911 of 5 stars$3.15+1.0%$8.50+169.8%-66.5%$84.48MN/A-1.32N/ATrending NewsEarnings ReportARCTArcturus Therapeutics2.8762 of 5 stars$11.39-4.4%$50.80+346.0%-3.8%$323.01M$152.31M-4.50180News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeCRVSCorvus Pharmaceuticals2.9068 of 5 stars$4.37+1.4%$15.00+243.2%+42.9%$321.15MN/A-4.3330News CoverageAnalyst RevisionABEOAbeona Therapeutics4.5008 of 5 stars$6.28+0.3%$19.25+206.5%+42.6%$320.24M$3.50M-4.9490Trending NewsEarnings ReportAnalyst ForecastOLMAOlema Pharmaceuticals1.631 of 5 stars$4.57-1.5%$24.50+436.1%-55.5%$317.48MN/A-2.2770News CoverageEarnings ReportAnalyst ForecastALDXAldeyra Therapeutics2.0673 of 5 stars$5.25-0.2%$9.50+81.0%+2.7%$315.05MN/A-6.1810Trending NewsInsider TradeAnalyst RevisionAMRNAmarin0.1972 of 5 stars$14.94-0.3%$12.00-19.7%+26.5%$310.40M$228.61M-4.07360Positive NewsBNTCBenitec Biopharma1.7438 of 5 stars$11.90+0.8%$26.00+118.5%+51.3%$309.76M$80K-7.8820News CoveragePositive NewsRCKTRocket Pharmaceuticals4.8433 of 5 stars$2.92+2.1%$16.33+459.4%-83.6%$308.61MN/A-1.16240Analyst RevisionINBXInhibrx Biosciences1.9596 of 5 stars$21.40+1.6%N/A+88.2%$304.86M$200K0.18166News CoverageEarnings ReportShort Interest ↓NGNENeurogene1.9309 of 5 stars$20.35-4.1%$46.17+126.9%-42.4%$302.64M$930K-4.6890News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies Arcturus Therapeutics Competitors Corvus Pharmaceuticals Competitors Abeona Therapeutics Competitors Olema Pharmaceuticals Competitors Aldeyra Therapeutics Competitors Amarin Competitors Benitec Biopharma Competitors Rocket Pharmaceuticals Competitors Inhibrx Biosciences Competitors Neurogene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANRO) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access